Living Well 60+ July-August 2014 | Page 21

J U LY / A U G 2 0 1 4 THIS IS AN ADVERTISEMENT. Have you appointed a trusted person to manage your affairs? We can help you designate powers of attorney, healthcare surrogacy, and guardianship. Do you want to be confident about your asset transfers to the next generation? Let us help you with wills, testamentary trusts, special needs trusts, and estate settlements. Have you planned for later life care? We can help you protect your assets for Medicaid eligibility, handle your crisis planning and VA pension planning. Providing personal legal advice to the Central Kentucky region. Carolyn L. Kenton Amy E. Dougherty BLUEGRASS ELDERLAW 120 North Mill Street, Suite 300 Lexington, KY 40507 859.281.0048 www.bgelderlaw.com 21 Baldness Breakthrough Scientists learning to generate new hair follicles by Angela S. Hoover, Staff Writer Although balding affects both men and women, men are hit the hardest by male-pattern baldness, or androgenetic alopecia. It strikes genetically predisposed individuals when a byproduct of testosterone called dihydrotestosterone (DHT) causes hair follicles on the scalp to shrink, producing everthinning hairs until the follicles eventually lose the capacity to produce hair that protrudes above the surface of the skin. Presently, there are only two FDA-approved treatments for male-pattern baldness: minoxidil (Rogaine), a vasodilator believed to prevent or slow follicle miniaturization by increasing nutrient supply, and finasteride (Propecia), which works by blocking the conversion of testosterone into DHT. Research has shown both can prevent or slow hair loss and sometimes induce regrowth by rescuing follicles that have begun to miniaturize. But neither can revive totally shrunken follicles. The only solution for this has been relocating healthy follicles to barren patches via invasive, expensive hair-transplant procedures. In the fall of 2013, researchers successfully identified molecular pathways that can be manipulated to generate new hair follicles. First considered possible in the 1950s when researchers observed new hair follicles forming during wound healing in rabbits and mice, the work was discredited until 2007, when dermatolo- gist George Cotsarelis from the University of Pennsylvania’s Perelman School of Medicine spotted hairs growing in the middle of small cuts made into the skin of adult mice. Cotsarelis and his colleagues determined these were de novo hair follicles formed in a process that looked a lot like embryogenesis. The wound-healing process causes skin cells to dedifferentiate, providing a limited time window during which those cells can be persuaded to form new hair follicles. In addition, inhibiting Wnt signaling during this window reduced follicle neogenesis, while overexpressing Wnt molecules in the skin increased the number of new follicles, according to a 2007 report in the journal Nature. (Wnt are signal transduction pathways that regulate cell-to-cell interactions during embryogenesis). Cotsarelis and his colleagues had discovered a potential way to generate new hair follicles. He formed a company called Follica in 2006 to develop new combination therapies to induce follicle neogenesis. Follica has patented a minimally invasive “skin perturbation” device that removes the top layers of skin, causing the underlying skin cells to revert to a stem-like state, after which a molecule is applied topically to direct the formation of new hair follicles. Preclinical and clinical trials have all resulted in new hair follicles in mice and humans. But Cotsarelis’ group has also learned that a protein called fibroblast growth factor 9 (Fgf9), which is secreted by gamma delta T cells in the dermis, plays a key role in the formation of new follicles during wound healing in adult mice. Fgf9 still needs to be tested on human skin in xenograft models and then in the clinic. There’s still a long way to go, but now there is real hope for banishing baldness.